technology

press releases

Date Title and Summary Additional Formats
Toggle Summary – PROMISE 2 pivotal trial completed enrollment and top-line data on track for 1H18 – – Eptinezumab Biologics License Application (BLA) submission on track for 2H18 – – Conference call scheduled for 5 p.m. ET today – BOTHELL, Wash. , Nov. 07, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. View HTML
Toggle Summary BOTHELL, Wash. , Nov. 01, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will webcast its presentation at the 26th Annual Credit Suisse Healthcare Conference at View HTML
Toggle Summary Conference call set for 5:00 p.m. EST November 7, 2017 View HTML
Toggle Summary -Clinical data demonstrated that eptinezumab, the only anti-CGRP monoclonal antibody in development administered by quarterly infusion, achieved a preventive benefit on the first day post-infusion and resulted in significant number of days of migraine freedom sustained for three months after first dose- View HTML
Toggle Summary BOTHELL, Wash., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics today announced that it will webcast its presentation at the upcoming Morgan Stanley 15 th Annual Global Healthcare View HTML
Toggle Summary — Positive top-line PROMISE 1 study results  further support eptinezumab's unique clinical profile — — $161.5 million from recent public offering expected to enable continued advancement of eptinezumab through pivotal studies, a planned Biologics License Application and achievement of other key View HTML
Toggle Summary Conference call set for 5:00 p.m. ET August 8, 2017 View HTML
Toggle Summary BOTHELL, Wash., July 18, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing its solely-owned pivotal-stage product candidate eptinezumab as the only anti-CGRP monoclonal antibody for the prevention of migraine administered View HTML
Toggle Summary BOTHELL, Wash., July 13, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing its solely-owned pivotal-stage product candidate eptinezumab as the only anti-CGRP monoclonal antibody for the prevention of migraine administered View HTML
Toggle Summary BOTHELL, Wash., July 12, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing its solely-owned pivotal-stage product candidate eptinezumab as the only anti-CGRP monoclonal antibody for the prevention of migraine administered View HTML